NHC
BIIB icon

Nicholas Hoffman & Company’s Biogen BIIB Stock Holding History

Nicholas Hoffman & Company’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,021
Closed -$215K – 263
2022
Q1 		$215K Sell
1,021
-53
-5% -$11.5K 0.01% 262
2021
Q4 		$258K Buy
1,074
+53
+5% +$13.6K 0.01% 243
2021
Q3 		$289K Sell
1,021
-35
-3% -$11.5K 0.05% 222
2021
Q2 		$366K Sell
1,056
-13
-1% -$3.94K 0.07% 194
2021
Q1 		$299K Buy
1,069
+31
+3% +$8.36K 0.06% 197
2020
Q4 		$254K Buy
+1,038
New +$268K 0.06% 201

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Nicholas Hoffman & Company's BIIB Position: Q2 2022 in Review

Nicholas Hoffman & Company sold out of Biogen (BIIB) in Q2 2022, closing a stake of 1,021 shares — an estimated $215K sold.

Nicholas Hoffman & Company first reported a position in BIIB in Q4 2020 and held it in 6 quarters. The position peaked at $366K in Q2 2021. 927 funds tracked by Wall St. Rank hold BIIB as of Q2 2022.

  • Nicholas Hoffman & Company reported no remaining Biogen position as of Q2 2022 after selling out during the quarter.
  • Nicholas Hoffman & Company sold 1,021 Biogen shares in Q2 2022, an estimated $215K.
  • Nicholas Hoffman & Company first reported a position in Biogen in Q4 2020 and held it in 6 quarters.
  • Nicholas Hoffman & Company's Biogen position peaked at $366K in Q2 2021.
  • 927 funds tracked by Wall St. Rank held Biogen as of Q2 2022.

Based on Nicholas Hoffman & Company's 13F filing for Q2 2022, filed 9 Aug 2022.